Plain-English translation of NCT07400367 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a multi-strain probiotic supplement can help treat a condition called metabolic dysfunction-associated steatotic liver disease (MASLD)—which means too much fat has built up in your liver along with other health problems like high blood sugar, high blood pressure, or weight concerns. You would take the probiotic supplement daily while also receiving standard lifestyle guidance from a doctor. The researchers want to see if this combination reduces liver inflammation and improves your overall metabolic health.
Right now, there's no reliable medication for fatty liver disease, and many people struggle to make lasting lifestyle changes on their own—leading to serious complications like cirrhosis. This trial exists because recent research suggests that fixing the balance of bacteria in your gut might help reduce liver inflammation and improve how your body processes fat and sugar.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the probiotic supplement or a placebo (inactive) powder—one sachet mixed with water daily for about 12 weeks. Throughout the trial, you would also meet with a gastroenterologist (liver specialist) who will provide standard lifestyle modification education covering diet, exercise, and weight management. You'll have blood tests and possibly imaging scans done before, during, and after treatment to measure how well your liver is improving.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
Taiwan